Congruence Therapeutics and Ono Pharmaceutical Expand Partnership to Target Neurology and Immunology Programs
核心洞察
Congruence Therapeutics (搜索) and Ono Pharmaceutical have expanded their multi-target research partnership to include two additional programs focused on clinically validated targets in neurology and immunology.
The collaboration leverages Congruence's proprietary computational drug discovery platform Revenir™ (搜索) to discover small molecule modulators (搜索) and advance them to development candidate stage.
Congruence will receive an undisclosed upfront payment plus R&D funding, milestones, and royalties, while Ono gains option for exclusive worldwide development and commercialization rights.
Congruence Therapeutics (搜索) and Ono Pharmaceutical Co., Ltd. (搜索) announced the expansion of their existing multi-target research partnership through a new collaboration agreement covering two additional programs in neurology and immunology. The expanded partnership, announced March 2, 2026, builds on their original collaboration that began in December 2024.
Partnership Structure and Financial Terms
Under the new agreement, Congruence will lead efforts to discover small molecule modulators (搜索) targeting two clinically validated high-value targets in neurology and immunology, advancing them to the development candidate stage. Ono will have the option to secure exclusive worldwide rights to further develop and commercialize development candidates generated under the agreement.
Congruence will receive an undisclosed upfront payment and is eligible for additional payments upon achievement of milestones in discovery, development, approval and commercialization, plus tiered royalties based on annual net sales of related products. Ono will also reimburse Congruence for internal and external research costs incurred in connection with the expanded partnership activities.
Revenir™ Platform Technology
The collaboration continues to leverage Congruence's proprietary computational drug discovery engine, Revenir™ (搜索), which systematically captures the biophysical features of proteins in different functional states to enable a highly differentiated approach to small-molecule discovery. The platform examines surface features and biophysical descriptors across protein conformers to predict small molecule induced modulation of physiologic protein states.
"We are excited to expand our partnership with Ono, a global pioneer of innovative medicines," said Sharath Hegde PhD, Chief Scientific Officer of Congruence. "The expansion is a testament to the significant contributions we have made in our existing collaboration as well as the trust and confidence we continue to build with Ono."
Clinical Pipeline Progress
Congruence's wholly owned program directed to MC4R-deficient genetic obesity (搜索) is entering a Phase 1/1b clinical study this month. The company will also nominate development candidates in the coming weeks for programs targeting GBA1-driven Parkinson's Disease (搜索) and Alpha-1 Antitrypsin deficiency (搜索).
The original collaboration between the companies focuses on leveraging Revenir™ (搜索) to discover novel small molecule correctors (搜索) directed to mutants of a difficult-to-drug cancer (搜索) target.
Strategic Significance
"Congruence's advanced computational discovery engine is attracting growing global attention with its lead program entering clinical development," said Seishi Katsumata, Corporate Officer / Executive Director, Discovery & Research of Ono. "We are honored that our ongoing collaboration with Congruence is expanding beyond oncology to other priority areas including both neurology and immunology."
The partnership represents Ono's commitment to accelerating drug development to deliver innovative medicines to patients with unmet medical needs. Congruence's platform-driven strategy supports a scalable approach to targeting genetically validated targets across multiple therapeutic areas including genetic obesity, neurological disorders, and rare diseases.